Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

247 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia.
Svicher V, Alteri C, Gori C, Salpini R, Marcuccilli F, Bertoli A, Longo R, Bernassola M, Gallinaro V, Romano S, Visca M, Ursitti A, Feasi M, Micheli V, Angelico M, Cassola G, Parruti G, Gubertini G, De Sanctis GM, Ceccherini-Silberstein F, Cappiello G, Spanò A, Perno CF. Svicher V, et al. Among authors: micheli v. Dig Liver Dis. 2010 Dec;42(12):902-7. doi: 10.1016/j.dld.2010.04.017. Epub 2010 Jun 19. Dig Liver Dis. 2010. PMID: 20621632
Clinical validation and applicability of different tipranavir/ritonavir genotypic scores in HIV-1 protease inhibitor-experienced patients.
Saracino A, Monno L, Tartaglia A, Tinelli C, Seminari E, Maggiolo F, Bonora S, Rusconi S, Micheli V, Lo Caputo S, Lazzaroni L, Ferrara S, Ladisa N, Nasta P, Parruti G, Bellagamba R, Forbici F, Angarano G. Saracino A, et al. Among authors: micheli v. Curr HIV Res. 2009 Jul;7(4):425-33. doi: 10.2174/157016209788680525. Curr HIV Res. 2009. PMID: 19601778 Free article.
Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group.
Svicher V, D'Arrigo R, Alteri C, Andreoni M, Angarano G, Antinori A, Antonelli G, Bagnarelli P, Baldanti F, Bertoli A, Borderi M, Boeri E, Bonn I, Bruzzone B, Callegaro AP, Cammarota R, Canducci F, Ceccherini-Silberstein F, Clementi M, Monforte AD, De Luca A, Di Biagio A, Di Gianbenedetto S, Di Perri G, Di Pietro M, Fabeni L, Fadda G, Galli M, Gennari W, Ghisetti V, Giacometti A, Gori A, Leoncini F, Maggiolo F, Maserati R, Mazzotta F, Micheli V, Meini G, Monno L, Mussini C, Nozza S, Paolucci S, Parisi S, Pecorari M, Pizzi D, Quirino T, Re MC, Rizzardini G, Santangelo R, Soria A, Stazi F, Sterrantino G, Turriziani O, Viscoli C, Vullo V, Lazzarin A, Perno CF; OSCAR Study Group. Svicher V, et al. Among authors: micheli v. New Microbiol. 2010 Jul;33(3):195-206. New Microbiol. 2010. PMID: 20954437 Free article.
Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study.
Prosperi MC, Mackie N, Di Giambenedetto S, Zazzi M, Camacho R, Fanti I, Torti C, Sönnerborg A, Kaiser R, Codoñer FM, Van Laethem K, Bansi L, van de Vijver DA, Geretti AM, De Luca A; SEHERE consortium. Prosperi MC, et al. J Antimicrob Chemother. 2011 Aug;66(8):1886-96. doi: 10.1093/jac/dkr171. Epub 2011 May 30. J Antimicrob Chemother. 2011. PMID: 21624929
A prognostic model for estimating the time to virologic failure in HIV-1 infected patients undergoing a new combination antiretroviral therapy regimen.
Prosperi MC, Di Giambenedetto S, Fanti I, Meini G, Bruzzone B, Callegaro A, Penco G, Bagnarelli P, Micheli V, Paolini E, Di Biagio A, Ghisetti V, Di Pietro M, Zazzi M, De Luca A; ARCA cohort. Prosperi MC, et al. Among authors: micheli v. BMC Med Inform Decis Mak. 2011 Jun 14;11:40. doi: 10.1186/1472-6947-11-40. BMC Med Inform Decis Mak. 2011. PMID: 21672248 Free PMC article.
Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score.
De Luca A, Di Giambenedetto S, Maserati R, Gianotti N, Narciso P, Antinori A, Di Perri G, Prosperi MC, Baldanti F, Micheli V, Zazzi M, Perno CF, Santoro MM; TMC114-C226 study group; ARCA study group. De Luca A, et al. Among authors: micheli v. Antivir Ther. 2011;16(4):489-97. doi: 10.3851/IMP1799. Antivir Ther. 2011. PMID: 21685536
Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development.
Svicher V, Cento V, Salpini R, Mercurio F, Fraune M, Beggel B, Han Y, Gori C, Wittkop L, Bertoli A, Micheli V, Gubertini G, Longo R, Romano S, Visca M, Gallinaro V, Marino N, Mazzotta F, De Sanctis GM, Fleury H, Trimoulet P, Angelico M, Cappiello G, Zhang XX, Verheyen J, Ceccherini-Silberstein F, Perno CF. Svicher V, et al. Among authors: micheli v. Dig Liver Dis. 2011 Dec;43(12):975-83. doi: 10.1016/j.dld.2011.07.002. Epub 2011 Aug 9. Dig Liver Dis. 2011. PMID: 21831732
Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection.
Svicher V, Cento V, Bernassola M, Neumann-Fraune M, Van Hemert F, Chen M, Salpini R, Liu C, Longo R, Visca M, Romano S, Micheli V, Bertoli A, Gori C, Ceccherini-Silberstein F, Sarrecchia C, Andreoni M, Angelico M, Ursitti A, Spanò A, Zhang JM, Verheyen J, Cappiello G, Perno CF. Svicher V, et al. Among authors: micheli v. Antiviral Res. 2012 Jan;93(1):86-93. doi: 10.1016/j.antiviral.2011.10.022. Epub 2011 Nov 9. Antiviral Res. 2012. PMID: 22086128 Free article.
Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing.
Armenia D, Vandenbroucke I, Fabeni L, Van Marck H, Cento V, D'Arrigo R, Van Wesenbeeck L, Scopelliti F, Micheli V, Bruzzone B, Lo Caputo S, Aerssens J, Rizzardini G, Tozzi V, Narciso P, Antinori A, Stuyver L, Perno CF, Ceccherini-Silberstein F. Armenia D, et al. Among authors: micheli v. J Infect Dis. 2012 Feb 15;205(4):557-67. doi: 10.1093/infdis/jir821. Epub 2012 Jan 11. J Infect Dis. 2012. PMID: 22238474 Free PMC article.
247 results